^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    senl_BCMA

    i
    Other names: senl_BCMA, BCMA CAR-T cells, Senl_BCMA03
    Associations

    News

    Trials
    Company:
    SenlangBio
    Drug class:
    BCMA-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    1year
    High Efficacy and Safety of Nanobody Based Anti-BCMA CAR-T Cell Therapy in Treating Patients with Relapsed or Refractory Multiple Myeloma (ASH 2023)
    Methods Autologous peripheral blood lymphocytes were collected from patients, who subsequently underwent intravenous fludarabine (30mg/m2/d) and cyclophosphamide (300mg/m2/d) lymphodepletion chemotherapy from day-5 to day -3. Conclusions The clinical trial demonstrated that BCMA CAR-T therapy, composed of dual nanobody VHHs targeting BCMA (dVHHs), exhibits a high ORR with a manageable safety profile in treating R/R MM patients. This extends even to high-risk patients, such as those with extramedullary lesions, cytogenetics high-risk groups, and patients with plasma cell leukemia or anaplastic plasma cell tumor.
    Clinical • CAR T-Cell Therapy • IO biomarker
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    cyclophosphamide • fludarabine IV • senl_BCMA
    2years
    The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Hebei Senlang Biotechnology Inc., Ltd.
    New trial
    |
    CD8 (cluster of differentiation 8) • IL6 (Interleukin 6) • CD4 (CD4 Molecule) • IL10 (Interleukin 10)
    |
    cyclophosphamide • senl_BCMA